Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00249808
Status:
COMPLETED
Last Update Posted:
2018-03-20
First Post:
2005-11-04
Brief Title:
A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed Have a Contraindication to or Are Intolerant of Other Systemic Therapies
Sponsor:
Merck KGaA Darmstadt Germany
Organization:
Merck KGaA Darmstadt Germany
Organization Data
Organization:
Merck KGaA Darmstadt Germany
Class:
INDUSTRY
Study ID:
25300
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Merck KGaA Darmstadt Germany
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None